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Parathyroidectomy in dialysis patients. Subtotal parathyroidec- metabolites, or intravenous calcitriol, the mean annual
tomy or total parathyroidectomy (PTx) with autotransplanta- incidence of parathyroidectomy (PTx) among all renal
tion are surgical procedures considered while the patient is replacement therapy (RRT) patients included in the Eu-included on the waiting list for renal transplantation. Total
ropean Dialysis and Transplantation Registry was similarPTx alone is based in the posibility that a fragment of tissue
(nodular hyperplasia in particular) left in the same pathophysi- in the periods 1983 to 1985 and 1986 to 1988 [1]. More
ological environment of long term dialysis would show the same recent reports showed that the incidence of PTx in pa-
behavior and reproduce in time the same clinicopathological tients who started RRT between 1990 and 1992 was nopicture. The persistence of uremia induces a continued growth
different from that observed in patients who started RRTstimulus developping residual hyperplasia and consequently a
very high risk of recurrence. We performed total PTx alone between 1983 and 1985 [2].
in 15 uremic patients excluded for renal transplantation 10 The prevalence of PTx in almost 14,180 patients in-
patients with undetectable iPTH serum concentration and were cluded in the Lombardy Registry who received RRTfollowed up for 37 to 144 months. There was no evidence of
between 1983 and 1996 was 9.2% after 10 to 15 years,clinical bone disease (bone pain or fractures). Bone mineral
and increased with the duration of RRT to 20.8% afterlumbar spine and hip density was measured at the end of
follow-up. The z score data showed that all patients had a bone 16 to 20 years This figure is even higher in other reports
mass similar than that expected for their age. Bone biopsies with 40% after 15–20 years of treatment [3]. Prolonga-
performed in four patients showed a uniform picture of low
tion of uremic state explains this high prevalence of para-turnover without aluminium staining. Calcification of small
thyroidectomy in this group of patients. The relative riskarteries (digital and arcade vessels in hands and feet) were
evaluated pre and post total PTx alone in nine out of the 10 factors for PTx were significantly higher in women and
patients with undetectable PTH levels.The small vessel calcifi- lower in elderly and diabetic patients. The relative risk
cation was present in five patients at the moment of PTx. At
for PTx (adjusted for gender, age, and nephropathy) wasthe end of the long term follow-up only one patient showed
higher in the patients on peritoneal dialysis than in thoseprogression. In conclusion, total PTx without autotransplanta-
tion is a very effective and adecuate treatment for refractory on hemodialysis and decreased after transplantation [2].
severe hyperparathyroidism in patients excluded for renal
transplantation. Aluminium related osteopathy post PTx is a
risk to be controlled with aluminium “free” dialysis water and PARATHYROID HYPERPLASIA RESISTENT
avoiding aluminium containing phosphate binders. TO CALCITRIOL
One of the characteristic features of very severe sec-
ondary hyperparathyroidism in uremic patients is para-Although the majority of patients with secondary hy-
thyroid hyperplasia. There are two types of parathyroidperparathyroidism caused by chronic renal failure are
hyperplasia: diffuse hyperplasia and nodular hyperpla-successfully managed medically, in a considerable num-
sia. The latter exhibits at least one well circumscribedber of patients with refractory symptoms, palliative surgi-
encapsulated nodule and each nodule usually consists ofcal treatment is necessary.
a single cell type with fat-free accumulation. As the gland
becomes heavier the hyperplastic pattern changes from
PREVALENCE AND RISK FACTORS
initial diffuse hyperplasia to nodular hyperplasia, and
In spite of the introduction of new therapeutical ap- ultimately to a single nodule. Nodular hyperplasia is the
proaches, such as new phosphate binders, vitamin D more advanced type of hyperplasia and is seen more
often in large glands where monoclonal proliferation
may be present irrespective of the size of the nodule [4].Key words: chronic dialysis, parathyroidectomy, parathyroid hyper-
plasia. Cells in nodular hyperplasia have a significantly lower
density of vitamin D receptors [5] and lower calcium 2002 by the International Society of Nephrology
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sensor receptors [6] than those in diffuse hyperplasia. there is a high degree of operator dependence, and be-
These findings can explain the resistance of parathyroid cause the risk of complications such as laryngeal palsy,
cells in parathyroid glands with nodular hyperplasia to the difficulty of a surgical exploration following failed
calcitriol therapy. This is a very important point in terms ethanol ablation, and the limited experience, the tech-
of clinical management of secondary hyperparathyroid- nique is regarded as experimental alternative to para-
ism since more than 85% of the parathyroid glands thyroidectomy.
weighing more than 500 mg exhibit nodular hyperplasia
Surgical parathyroidectomy[7] and patients with at least one gland larger than 0.5
cm3 or 1 cm in diameter are usually refractory to calcitriol Three main types of surgical approaches have been
pulse therapy in the long term [8]. It is also important advocated for PTx: subtotal parathyroidectomy, total
to consider that, with time on dialysis, the size of the parathyroidectomy with parathyroid autotransplanta-
parathyroids increases and an ever higher proportion of tion, and total parathyroidectomy without autografting.
patients also show nodular rather than diffuse hyper- Subtotal parathyroidectomy, and total parathyroidec-
plasia [9]. tomy with parathyroid autotransplantation. Many au-
Arnold et al examined hyperplastic glands with sec- thors recommend subtotal PTx or total PTx with auto-
ondary hyperparathyroidism and 75% of the glands re- transplantation although both procedures carry some
vealed monoclonal growth [10]. Therefore, nodular hyper- disadvantages, including the risks of permanent hypo-
plasia is the commonest histological finding in secondary parathyroidism and recurrence of bone disease [16–17].
hyperparathyroidism. Forty three out of 60 patients (72%) Results obtained with subtotal PTx are very similar to
in our series of parathyroidectomies in chronic renal total PTx with autotransplantation [18] and recurrent or
failure patients showed nodular hyperplasia [11]. persistent hyperparathyroidism is presented in 5–15%
of cases. However, most published series have a mean
follow up period of less than 3 years and some series doINDICATIONS FOR PARATHYROIDECTOMY
not distinguish between patients remaining on dialysisParathyroid gland size and PTH levels 8–20-fold above
and those who have been transplanted.the normal range are critical for long term prognosis
Renal failure is a powerful stimulus for parathyroidof calcitriol pulse therapy in chronic dialysis patients
cell proliferation, and if there is any residual parathyroid(abstract; Kitaoka et al, J Am Soc Nephrol 2:637A, 1991)
tissue after parathyroid surgery and the patient remainsand severe nodular parathyroid hyperplasia is found in
on dialysis for several years, then the autonomus hyper-many such patients. Ritz et al proposed that parathyroid-
parathyroidism is likely to recur. Gagne´ et al [19] ob-ectomy should be seriously considered when the parathy-
served that among the twelve patients with a time periodroid mass, as estimated by imaging procedures exceeds
of more than 90 months after subtotal parathyroid sur-approximately 1 cm3 or 1 gr [13].
gery, eight had recurrence of severe hyperparathyroid-Clasical indications for parathyroidectomy are severe
ism with intact PTH levels500 pg/mL. Higgins et al [20]hyperparathyroidism (PTH 1000 pg/mL) resistant to
also showed a high recurrence of hyperparathyroidismmedical therapy in the presence of: hypercalcemia, bone
more than 5 years after total parathyroidectomy with anpain, and severe hyperparathyroid bone disease, metas-
autograft with only 20% of patients remaining on dialysistasic calcifications, intractable pruritus, or otherwise un-
having normal PTH concentrations.explained symptomatic myopathy. Enlarged parathyroid
Tominaga et al [21] have recently published the resultsglands detected by ultrasound (glandular weight over
of 1053 patients on dialysis who underwent total para-500 mg) are very frequently nodular hyperplastic glands
thyroidectomies with forearm autograft. In order to avoidand hyperparathyroidism may be refractory to medical
the remaining supernumerary glands they routinely per-treatment
formed excision of the fat tissue sorrounding the parathy-
roid glands, bilateral removal of the thymic tongue, and
TREATMENT OF REFRACTORY bilateral opening of the carotid sheats. They selected
HYPERPARATHYROIDISM diffuse type hyperplasic tissue for grafting or, if im-
Ethanol injection possible, fragments from the smallest gland. In spite of
this excellent surgical strategy, persistent hyperparathy-Selective percutaneous ethanol injection into the largest
roidism was diagnosed in 4% of the patients and theglands until PTH levels falls to less than 200 pg/mL has
incidence of recurrent hyperparathyroidism was 10% inbeen advocated [14]. In a survey in 46 patients resistant
the third year, 20% in the fifth year, and 30% in theto calcitriol pulse therapy all glands larger than 5 mm
seven years after parathyroidectomy. When nodularin diameter were destroyed by ethanol guided by power
hyperplasic glands were autografted, the incidence ofDoppler flow mapping. Serum iPTH levels decreased
from 633 359 to 289 222 after one year [15]. However recurrence was significantly higher than when diffuse
de Francisco et al: Parathyroidectomy in dialysis patients S-163
hyperplasia was transplanted (60% and 20% at 10 years after gland biopsies or to additional sites of parathyroid
tissue. Ljutic et al [28] reported 27 patients who under-for nodular and diffuse, respectively).
Therefore, there is a high incidence of recurrent hyper- went total PTx with four or more glands removed and
immunologically detectable PTH persisting in 23, andparathyroidism in patients who remain on long term
dialysis. But in some series, subtotal parathyroidectomy concluded that PTx was incomplete in the majority of
patients. Stracke et al reported a high percentage of pa-or total parathyroidectomy with autograft are frequently
followed by hypoparathyroidism. Gagne´ et al [19] in a tients with detectable PTH: considering only those pa-
tients in which four or more parathyroid glands wereretrospective study performed in chronic hemodialysis
concluded that, although excellent short term results removed, PTH levels were less than normal in three
patients, normal in five patients, and increased in sevenwere obtained with both procedures, satisfactory long
term control of parathyroid gland function was achieved patients at follow-up [29] The persistence of uremia in-
duces a continued growth stimulus developing residualin only one third of the patients, the other two thirds
remaining either hypoparathyroidic or developing recur- hyperplasia.
The main drawback of total PTx alone is the increasedrent hyperparathyroidism, and recurrence of hyperpara-
thyroidism was more frequent with nodular autografting risk of adynamic bone disease and, for some authors,
the possibility of vascular calcifications.The problem of origin of oversecretion of PTH after
total parathyroidectomy with forearm implant. Reopera-
tions in the cervical region are associated with high com-
LONG TERM SUCCESSFUL TOTAL
plication rates and implantation of parathyroid tissue in
PARATHYROIDECTOMY WITHOUT
the forearm was developed to allow, if necessary, re-
AUTOGRAFTING IN SANTANDER
moval of parathyroid tissue. However there have been
Ten patients under hemodialysis therapy at Valdecillareports of patients in whom the implanted tissue contin-
Universitary Hospital (Santander) were treated with to-ued to grow with alarming rapidity [22–24]. Transplanted
tal parathyroidectomy for uncontrolled secondary hy-parathyroid fragments derived from glands weighing
perparathyroidism in the time period between 1989 andmore than 0.5 g, and consequently showing nodular hy-
1999. The patients were selected among 15 patientsperplasia, relapse frequently [7]. Resection of the grafted
treated with four glands parathyroid extirpation due totissue usually removes all palpable parathyroid nodules
very low or undetectable parathyroid hormone levels forand is not always followed by a reduction in the PTH
more than two years after surgery. All were excludedsecretion, since parathyroid tissue has ability to migrate
for renal transplantation.away from the implantation [25].
Age, gender, renal disease, age at PTx, time on dialysisUsually it is not difficult to diagnose graft dependent
before and after total PTx, gland histology, PTH at sur-recurrent HPT based on PTH gradient and image tech-
gery and at the end of follow-up, are shown in Table 1.niques. However sometimes it is difficult to localize the
Nine patients were on hemodialysis 4 h three times asource of hormone excess, i.e., autografted parathyroid
week, and one patient was under CAPD. The indicationtissue, residual parathyroid glands in neck or mediasti-
of PTX was made because of vitamin D resistent severenum, implantation of parathyroid tissue in surrounding
clinical, biochemical, and radiological hyperparathyroid-tissue, or metastasis of parathyroid carcinoma. We have
ism with confirmed histological osteitis fibrosa alumin-developed a technique for localizing the origin. It involves
ium negative in four cases. All patients had an increasetotal ischemic blockade of the graft bearing arm using
in PTH above ten times the normal range with normaltourniquet and measurement of circulating iPTH levels.
or elevated serum calcium.If the serum level of circulating iPTH rapidly decreases
Total parathyroidectomy was performed in the stan-during blockade of graft bearing arm (PTH mean life 2
dard manner and all removed material was histologicallymin), this suggests that the origin of excess PTH secretion
examined. One half of each parathyroid gland was main-is the autograft whereas when the iPTH level does not
tained by criopreservation in each case. During the post-change during blockade the origin is possibly parathyroid
operative period patients were treated with supplemen-tissue located in the neck or mediastinum [26].
tal calcium and calcitriol in order to maintain normalTotal PTx without autografting. Total PTx is based in
serum calcium levels. Patients were followed-up 37 tothe possibility that a fragment of tissue (nodular hyper-
144 months.plasia in particular) left in the same pathophysiological
Studies were performed at the end of follow-up postenvironment of long term dialysis would show the same
total PTx calcium, phosphate, and bone serum markersbehavior and reproduce in time the same clinicopatho-
such as osteocalcine, bone phosphatase alkaline, carboxi-logical picture. However, total PTx may not be total.
terminal cross-linked telopeptide type I collagen, andDetectable parathyroid hormones have been reported
carboxyterminal propeptide of type I procollagen andeven after total PTx in many patients [27], probably due
either to fragments of parathyroid tissue left in place bone biopsy (obtained in four patients) are shown in
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Table 1. Details of patients who underwent total parathryoidectomy (PTx) without autografting
On dialysis After PTx PTH level
Patient Gender Renal disease Age at PTx Months Pre Post Histology
DFL F Interstitial 63 128 144 650 5 HD
TGR F Interstitial 68 250 76 1000 5 HN
CAO F Congenital 35 120 72 2308 5 HN
CFF M Glomerular 62 140 72 940 6 HD
HAM M Interstitial 72 80 56 1374 5 HN
PPR M Vascular 50 120 50 1150 5 HN
LTC F Glomerular 47 14 48 2206 5 HN
NGS M Vascular 53 17 41 2082 5 HN
SCR F Unknown 35 204 39 1100 5 HD
PLC F Interstitial 50 60 37 1541 5 HN
Normal range of IPTH is 10 to 60 pg/mL. Abbreviations are: HD, diffuse hyperplasia; HN, nodular hyperplasia; F, female; M, male.
Table 2. Follow up of serum bone markers after total PTx without autotransplantation
Months Calcium Phosphate BAP Osteocalcine Telopeptide Propeptide
Patient after PTX (8.5–10 mg/dL) (3.0–5.0 mg/dL) (10–22 UL) (10–40 ng/mL) (1.8–5 ng/mL) (69–163 ng/mL) Bone biopsy
DFL 144 8.8 5.3 9.1 70 37 97 ABD Al neg
TGR 76 9.2 6.1 13.5 86 38 76 ABD Al neg
CAO 72 8.3 4.2 14.5 60 23 183 —
CFF 72 10.1 3.9 13 68 28 67 —
HAM 56 9.8 6.3 12.8 61 27 106 ABD Al neg
PPR 50 9.6 5.8 21.2 24 43 184 ABD Al neg
LTC 48 9.1 4.9 13.9 31 22 178 —
NGS 41 8.9 3.3 19 24 34 74 —
SCR 39 10.2 4.5 10.1 61 33 104 —
PLC 37 9.5 6.8 14.2 109 96 140 —
ABD is adynamic bone disease.
Table 3. Bone mineral density in patients at the end of follow-up nia was present in four patients in L1-L4 and in five
patients at femoral neck (more than 1 SD below theL1–L4 Femoral neck
mean of peak bone mass (T1). Z score data showedPatient BMD g/cm2 T Z score BMD g/cm2 T Z score
that all patients had a bone mass similar than that ex-
DFL 1.001 0.42 1.20 0.649 2.45 0.64
pected for their age [30].TGR 0.629 3.80 1.80 0.596 2.98 0.80
CAO 1.153 0.97 1.02 0.905 0.10 0.34 Similar results in BMD were obtained by Kaye et al
CFF 0.962 1.17 0.52 0.748 2.10 0.51 [27] in a long term follow up study (mean 3.8 years)
HAM 1.297 1.87 2.81 0.721 2.34 0.03
following elective total parathyroidectomy in 13 patients.PPR 0.858 2.12 1.78 0.788 1.81 0.65
LTC 1.358 2.83 3.33 1.021 1.26 2.01 They observed increments in bone mineral density in all
NGS 0.975 1.05 0.63 0.768 1.99 0.72 patients except two which showed a small decline. At
SCR 1.390 3.12 3.21 0.833 0.62 0.33
the same time, bone histomorphometry in six patients aPLC 0.928 1.08 0.32 0.864 0.30 0.70
median of 1.5 years following PTX showed a uniform
picture of low turnover. Other studies have also shown
an increase in BMD after successful parathyroidectomy,
Table 2. Bone mineral density measurements for lumbar with better recovery in patients with osteoporosis [31].
spine and hip (dual X ray absorptiometry) are shown in Increments in bone mineral density are explained by a
Table 3. Skeletal surveys at surgery and at the end of the higher depression in resorption than in formation.
study were compared by two of the authors. Peripheral
Bone biopsy: Adinamic bone diseasevascular calcifications were studied with X ray films of
hands and feet Four patients who underwent bone biopsy 50, 56, 76,
and 144 months after total PTx showed adynamic bone
Bone mineral density disease with low bone turnover aluminium negative char-
At the end of follow-ups after total PTx only one out acterized by low bone resorption and formation with
of the 10 patients had BMD in the range of osteoporosis normal or low osteoid tissue. There is a legitimate con-
at L1-L4 and at femoral neck sites (more than 2.5 SD cern that the complete or near complete removal of
parathyroid hormone may have deleterious consequencesbelow the mean of peak bone mass (T2.5). Osteope-
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for the skeleton. Unfortunately we could not study all products (AGEs), warfarin and possibly other poorly de-
fined elements of the uremic milieu may all contributepatients with bone histology, but this histological picture
is universally associated with low levels of PTH, and to vascular calcification [42]. The extent of arterial calci-
fication increases also with age and the duration of dial-most dialysis patients with a PTH 100 ng/L will have
adinamic bone disease [32]. The changes in biochemical ysis [43]. Patients with adynamic bone disease are more
susceptible to develop iatrogenic hypercalcemia whichbone markers correspond to histological findings with
an important reduction in resorptive activity. may result in arterial calcifications caused by the use of
calcium and lower metabolic activity. Among our patientsLow bone remodelling lesions are quite frequent ac-
counting in some series for almost one half the lesions with total absence of PTH, progression of small vessel
calcification was not particularly observed. Nevertheless,observed in patients under dialysis treatment [33–34].
Years ago this condition was ascribed to aluminium bone more sensitive methods (helical or electron-beam com-
puted tomography) should be used to assess vascularintoxication [35], a form of the disease associated with
substancial morbidity in the form of bone pain and in- calcifications. Since aortic stiffness and calcification are
related to cumulative amount of calcium-containing phos-creased fracture incidence [37]. Nowadays most cases
are clearly unrelated to aluminium [33], a form generally phate binders consumed, it is prudent to aim for a rigor-
ous control of calcium phosphate based in non calciumasymptomatic, and the majority of patients with low bone
remodelling we see now are free of symptoms, and many containing phosphate binders in uremic patients and par-
ticularly in hypoparathyroid dialysis patients [44].of them should not be considered as having disease. Most
of the evidence in patients with low bone remodelling
indicates that the incidence of bone pain, hypercalcemia,
CONCLUSION
and bone fractures is related to the presence of more
Which is the best surgical procedure to the manage-than 20% of bone surface covered by aluminium [33, 37].
ment of vitamin D resistant severe secondary hyper-An association of total PTx with adverse long-time ef-
parathyroidism in dialysis patients? We believe that forfects on bone in the absence of aluminium bone disease
patients not included in the waiting list for renal trans-has not been described in the literature. No clinical bone
plantation, total parathyroidectomy alone should consid-disease associated with low PTH was observed in our
ered. One important advantage is the absence of recur-patients. Carpal tunnel syndrome and/or shoulder pain
rence. Long term follow-up of 10 hypoparathyroid patientsin two patients under dialysis for six and eleven years
with histologically proven adynamic bone disease alu-were related to 2 amyloidosis.
minium negative revealed good clinical tolerance, bone
Radiology: Fractures and vascular calcifications mineral mass similar to that expected for their age, no
evidence of fractures, and no significant progression inAlthough lower PTH less than 195 pg/mL has been
small vessel calcifications.related to an increase in the risk of having a hip fracture
[38], and a reduced bone turnover will reduce the capac- Reprint requests to Dr. Angel L.M. de Francisco, Servicio de Nefro-
ity of bone to repair microfractures resulting in an in- logı´a, Hospital U Valdecilla, Universidad De Cantabria, Santander,
Spain.crease fracture risk independent of bone mass [38–40],
E-mail: martinal@unican.esradiological fractures were not detected in any patient
in this study.
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